FDA Advisors Recommend Ending Clozapine REMS Program
Two FDA advisory panels have recommended eliminating the Risk Evaluation and Management Strategy (REMS) for clozapine, an antipsychotic drug used for treatment-resistant schizophrenia, citing that the current restrictions hinder access to the medication. While clozapine can cause severe neutropenia, the panels argue that the REMS requirements are overly burdensome and not necessary for safe use. Public testimony highlighted the negative impact of REMS on patient access, with many advocating for its removal to improve treatment availability.